Recent research have centered on the intersection of GLP|glucose-dependent insulinotropic polypeptide|GCGR stimulant therapies and dopaminergic communication. While GLP activators are widely employed for treating type 2 T2DM, their unexpected effects on reinforcement circuits, specifically govern